Molecular properties of WHO essential drugs and provisional biopharmaceutical classification.

By N. A. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernäs, A. Hussain, H. Junginger, S. Stavchansky, K. Midha, V. Shah and 1 more. Molecular Pharmaceutics, 2004

848 citations recorded by the source corpus.

Subfields: Analytical Chemistry, Oncology, Pharmaceutical Science

View Paper: https://www.semanticscholar.org/paper/6253c197a9d3a2e56a652738f544a53ca6038e56

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. L. Benet
2. Colin W. Pouton
3. Chi‐Yuan Wu
4. D. McClements
5. Jiajia Rao

In Pharmaceutical Science

1. Christopher J. H. Porter
2. W. Charman
3. Natalie L. Trevaskis
4. S. Charman
5. H. Williams
6. R. Shanker
7. Colin W. Pouton
8. Chi‐Yuan Wu

Citations in the corpus

• Strategies to Address Low Drug Solubility in Discovery and Development (2013, background): “Similar trends are also evident with weak bases (which make up the larger proportion of ionizable drug candidates); for example, the aqueous solubility of enalapril maleate is 25 mg/ml (Kasim et al., 2004), whereas that of the free base is ;0.21 mg/ml.”
• Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System (2004, background): “For example, acetaminophen (bioavailability 88%), dapsone (93%), and theophylline (96%), all highly metabolized drugs, are listed as Class 4 compounds based only on physicochemical criteria (25), as opposed to their Classes 1 and 2 listings in Table I.”